Collegium Pharmaceutical/$COLL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Collegium Pharmaceutical
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
- Ticker
- $COLL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 423
- Headquarters
- Stoughton, United States
- Website
- www.collegiumpharma.com
COLL Metrics
BasicAdvanced
$718M
15.69
$1.41
0.76
-
Price and volume
Market cap
$718M
Beta
0.76
52-week high
$50.79
52-week low
$21.43
Average daily volume
877K
Financial strength
Current ratio
1.031
Quick ratio
0.703
Long term debt to equity
3.723
Total debt to equity
3.905
Interest coverage (TTM)
2.25%
Profitability
EBITDA (TTM)
405.255
Gross margin (TTM)
89.45%
Net profit margin (TTM)
5.93%
Operating margin (TTM)
21.24%
Effective tax rate (TTM)
38.32%
Revenue per employee (TTM)
$1,910,000
Management effectiveness
Return on assets (TTM)
5.75%
Return on equity (TTM)
17.61%
Valuation
Price to earnings (TTM)
15.69
Price to revenue (TTM)
0.871
Price to book
2.3
Price to tangible book (TTM)
-0.67
Price to free cash flow (TTM)
2.146
Free cash flow yield (TTM)
46.61%
Free cash flow per share (TTM)
10.277
Growth
Revenue change (TTM)
14.31%
Earnings per share change (TTM)
32.73%
3-year revenue growth (CAGR)
14.60%
3-year earnings per share growth (CAGR)
62.22%
10-year earnings per share growth (CAGR)
-6.28%
What the Analysts think about COLL
Analyst ratings (Buy, Hold, Sell) for Collegium Pharmaceutical stock.
Analyst projections of the future price of Collegium Pharmaceutical stock.
Bulls say / Bears say
JORNAY PM is delivering strong underlying growth: second-quarter revenue rose 41% year on year, prescriptions increased 13.1% and the number of prescribers reached a record. Collegium kept its full-year revenue outlook for the product unchanged. (Collegium Pharmaceutical)
AZSTARYS adds a second ADHD product with expected patent protection through 2037. It generated $12.9 million in revenue in the first weeks after the acquisition, and Collegium raised its 2026 revenue outlook for the drug to $65 million–$75 million. (Collegium Pharmaceutical)
BELBUCA is due to gain formulary access covering a further 9 million people from the fourth quarter of 2026. That broader access could support sales from the pain portfolio. (The Motley Fool)
Lower-than-expected pricing for authorised generic NUCYNTA products forced Collegium to cut its 2026 revenue outlook by $40 million at both ends of the range and its adjusted EBITDA outlook by $30 million. Further pricing weakness could weigh on earnings. (Collegium Pharmaceutical)
Teva has the contractual ability to launch a generic version of BELBUCA in January 2027. Collegium has an authorised-generic response, but competition could still pressure sales or pricing. (The Motley Fool)
The AZSTARYS acquisition has left the company with less balance-sheet flexibility: after using about $356 million in cash for the deal, Collegium reported $129.5 million in cash and net debt of about 2.1 times adjusted EBITDA. That leverage could limit its room to manoeuvre if growth disappoints. (Longbridge, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
COLL Financial Performance
Revenues and expenses
COLL Earnings Performance
Company profitability
Upcoming events
No upcoming events
COLL News
AllArticlesVideos
Funds containing COLL
AllUSDGBPEUR
Fund name | Fund size | $COLL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.04% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.